Standard BioTools Inc.
LAB
$1.07
-$0.11-9.32%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 64.40% | 48.49% | 29.36% | 32.45% | 8.98% |
| Total Other Revenue | -6.02% | 156.55% | 10.17% | -21.80% | 1.66% |
| Total Revenue | 64.03% | 48.23% | 29.25% | 31.27% | 8.57% |
| Cost of Revenue | 76.07% | 222.38% | 124.59% | 48.31% | 7.26% |
| Gross Profit | 47.12% | -24.01% | -31.21% | 14.69% | 10.47% |
| SG&A Expenses | 76.73% | 60.25% | 39.69% | 15.57% | -18.58% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 81.42% | 69.21% | 45.38% | 15.52% | -14.41% |
| Operating Income | -110.75% | -108.11% | -71.63% | 1.78% | 36.93% |
| Income Before Tax | -86.39% | -65.84% | -40.77% | 32.41% | 61.54% |
| Income Tax Expenses | 26.77% | -79.68% | 189.87% | 115.91% | 115.97% |
| Earnings from Continuing Operations | -86.03% | -64.53% | -40.99% | 31.14% | 60.73% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -86.03% | -64.53% | -40.99% | 31.14% | 60.73% |
| EBIT | -110.75% | -108.11% | -71.63% | 1.78% | 36.93% |
| EBITDA | -142.37% | -126.82% | -48.29% | 17.34% | 50.38% |
| EPS Basic | 41.45% | 25.93% | 15.31% | 40.19% | 61.39% |
| Normalized Basic EPS | 54.25% | 37.65% | 26.54% | 51.59% | 63.44% |
| EPS Diluted | 42.04% | 25.77% | 14.40% | 39.74% | 61.05% |
| Normalized Diluted EPS | 54.25% | 37.65% | 26.54% | 51.59% | 63.44% |
| Average Basic Shares Outstanding | 346.12% | 253.34% | 161.12% | 68.66% | 1.10% |
| Average Diluted Shares Outstanding | 346.12% | 253.34% | 161.12% | 68.66% | 1.10% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
